These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 12689599)

  • 21. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
    Pérez P; Kwon YJ; Alliende C; Leyton L; Aguilera S; Molina C; Labra C; Julio M; Leyton C; González MJ
    Arthritis Rheum; 2005 Sep; 52(9):2751-60. PubMed ID: 16142742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Polymorphisms of the Tissue Inhibitors of Metalloproteinases- 1 and -2 with Alzheimer's Disease in Taiwan.
    Ho WM; Lee YS; Chen CM; Wu YY; Hsu WC; Huang YH; Chen YC
    Curr Alzheimer Res; 2021; 18(6):505-512. PubMed ID: 34561981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MMP and TIMP expression pattern in pleural effusions of different origins.
    Eickelberg O; Sommerfeld CO; Wyser C; Tamm M; Reichenberger F; Bardin PG; Solèr M; Roth M; Perruchoud AP
    Am J Respir Crit Care Med; 1997 Dec; 156(6):1987-92. PubMed ID: 9412584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
    Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
    Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
    Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
    J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
    Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
    Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients.
    Mazanowska O; Zabińska M; Kościelska-Kasprzak K; Kamińska D; Krajewska M; Banasik M; Madziarska K; Zmonarski SC; Chudoba P; Biecek P; Boratyńska M; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2636-9. PubMed ID: 25380883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
    Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
    Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.
    Badra G; Lotfy M; El-Refaie A; Obada M; Abdelmonem E; Kandeel S; Fathy A
    Acta Microbiol Immunol Hung; 2010 Mar; 57(1):29-42. PubMed ID: 20350877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities.
    Jacob-Ferreira AL; Passos CJ; Jordão AA; Fillion M; Mergler D; Lemire M; Gerlach RF; Barbosa F; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2009 Oct; 105(4):281-8. PubMed ID: 19594729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C.
    Lichtinghagen R; Huegel O; Seifert T; Haberkorn CI; Michels D; Flemming P; Bahr M; Boeker KH
    Clin Chem; 2000 Feb; 46(2):183-92. PubMed ID: 10657374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.
    Kossakowska AE; Edwards DR; Lee SS; Urbanski LS; Stabbler AL; Zhang CL; Phillips BW; Zhang Y; Urbanski SJ
    Am J Pathol; 1998 Dec; 153(6):1895-902. PubMed ID: 9846979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Kulczyńska A; Koper OM; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2014; 40(2):351-7. PubMed ID: 24448781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.